GS-4774 is a heat-inactivated, yeast-based, T-cell vaccine designed to elicit hepatitis B virus (HBV)-specific T-cell responses. We evaluated the safety, tolerability and efficacy of GS-4774 in patients with chronic HBV infection.

Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B / Lok, Anna S; Pan, Calvin Q; Han, Steven-Huy B; Trinh, Huy N; Fessel, W Jeffrey; Rodell, Timothy; Massetto, Benedetta; Lin, Lanjia; Gaggar, Anuj; Subramanian, G Mani; Mchutchison, John G; Ferrari, Carlo; Lee, Hannah; Gordon, Stuart C; Gane, Edward J. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - 65:3(2016), pp. 509-16-516. [10.1016/j.jhep.2016.05.016]

Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B

FERRARI, Carlo;
2016

Abstract

GS-4774 is a heat-inactivated, yeast-based, T-cell vaccine designed to elicit hepatitis B virus (HBV)-specific T-cell responses. We evaluated the safety, tolerability and efficacy of GS-4774 in patients with chronic HBV infection.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11381/2814132
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 116
  • ???jsp.display-item.citation.isi??? 105
social impact